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Mesothelioma: Benefit from Surgical Resection is
Questionable
Tom Treasure, MS, MD, FRCS, FRCP and Martin Utley, PhD
Deaths from malignant pleural mesothelioma are increasing in number in Europe andare expected to peak between 2011 and 2015 in Britain. The burden of this disease
in the developing world is likely to be great. Is there anything we can do as surgeons to
influence a patient’s survival? Does radical surgery have a useful role? The report on 945
patients, from Memorial Sloan-Kettering Cancer Centre is by far the largest series of
patients reviewed to date.1 The data will inevitably be used by those planning and
designing randomized trials of treatment of MPM so the paper merits close attention and
very careful reading.
It is useful to first take a general look at the data to get a sense of their reliability.
The sample in this report was obtained from the pathology department database which
provided a list of patients in whom a diagnosis of mesothelioma was recorded. Clinical
information on these patients was then retrieved from the clinical data base, and the case
records, for analysis. In about half of the 945 patients, there was no record of the
histological classification and there was no pathological material available for review so
mesothelioma was entered as unclassified into the Cox proportional hazards model that
was constructed. There was also a high level of missing data; in half of the patients, the
stage was missing. This rings an alarm bell, particularly as there is likely to be more
complete histological and staging data in those operated upon within the institution than
unoperated patients, creating an imbalance that could distort comparisons between
treatment groups. No details are provided concerning data completeness by treatment
group.
In this practice the objective of surgery is implicitly extension of life; the report
makes no mention of symptom relief or quality of life despite extrapleural pneumonec-
tomy being a severe intervention with a high complication rate.2 The abstract concludes
with the sentence “Surgical resection in a multimodality setting was associated with
improved survival.” Having been operated upon may be associated with longer survival
but the word “improved” implies a belief that there is cause and effect. Is that belief
justified on these data? Is longer survival conferred by the act of surgery or merely
associated with the fact of surgery?
Surgical resection emerged as being significantly associated with longer survival
from a Cox proportional hazards model. The implication is that other factors including
tumor stage, smoking history, asbestos exposure, gender, pain, histology and laterality
(but apparently not age) are controlled for. The authors dichotomized each factor before
entering the data into the model; whether the dichotomics used were devised prior to
analysis or on inspection of the data is not specified. It is worth pointing out that putting
confounding variables into such a Cox model is not the same as “controlling” for the effect
of those confounding variables. For instance, consider the association between survival
and laterality, which we focus on because data are present for all 945 patients. The authors
combine right sided disease and bilateral disease despite bilateral disease being associated
with much poorer survival than right sided disease. None of those patients with bilateral
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disease will have had resection. Resection could therefore
emerge as a favorable factor independent of dichotomized
laterality solely as it would exclude those patients with
bilateral disease and hence very poor prognosis.
This type of effect undermines any interpretation of the
association of resection and longer survival as a causal
relationship. There is considerable scope for such effects,
particularly given the fact that staging and histology data
were missing in half of the cases.
There is another worrisome aspect to the analysis, that
being the exclusion of those patients who had a thoracotomy,
but in whom the intended resection was not achieved. These
174 patients represent about a third (31%) of those subjected
to thoracotomy and would of course remain within an
“operated” group in an intention to treat analysis. Not only
are they excluded from the surgical resection group, but
they are included in the group with which surgical results
are being compared. To spell it out, those patients entering
the model as having had “surgical resection” are twice
selected: once clinically in the hands of an expert team,
and then again on the basis of favorable features discov-
ered at surgery. The implications for the analysis aside, we
consider 31% having major exploratory surgery to repre-
sent a concerning burden in a population of patients
nearing the end of their lives.
Furthermore, would it not be as reasonable to attribute
survival differences between treatment groups to the adjuvant
therapies as to the surgery? The largest survival difference
was observed between those patients that had multi-modality
therapy compared to those that had resection alone. Indeed,
comparing figure 9 and 10 there is little difference between
the survival among those that had resection alone and those
that had no operation.
That said, in order to have received multiple treatments
you have to be a survivor in reasonable clinical state for a
sufficient length of time. This is a further reminder of the
importance of intention to treat analysis.
Our reservations about the possible interpretation of
this paper as providing evidence of benefit from surgical
resection does not stem from an obstinate refusal to accept
any evidence other than a randomized trial. There are many
operations for which we rely on other forms of evidence3 but
with surgery as severe as this, within the context of multi-
modality treatment and relatively small differences, analyses
of further case series are unlikely to produce an answer we
can trust.4
It is for exactly these reasons that we embarked on the
MARS (Mesothelioma and Radical Surgery) trial which is in
its pilot phase recruiting in Great Britain.5 This trial aims to
evaluate EPP within tri-modality therapy with a control arm
of any other treatment. Trials are not easy in surgery but it is
up to surgeons to deliver them. We must be willing to both
take a lead in developing them and to put our patients into
them.6 The study of Flores et al is the largest of its kind and
contains valuable data but the question of whether radical
surgery confers a net benefit on patients is still open and will
not be resolved by further case series.
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